Aurore Perrot

11.1k total citations
130 papers, 1.2k citations indexed

About

Aurore Perrot is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Aurore Perrot has authored 130 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Hematology, 61 papers in Oncology and 54 papers in Molecular Biology. Recurrent topics in Aurore Perrot's work include Multiple Myeloma Research and Treatments (103 papers), Peptidase Inhibition and Analysis (33 papers) and Protein Degradation and Inhibitors (32 papers). Aurore Perrot is often cited by papers focused on Multiple Myeloma Research and Treatments (103 papers), Peptidase Inhibition and Analysis (33 papers) and Protein Degradation and Inhibitors (32 papers). Aurore Perrot collaborates with scholars based in France, United States and Spain. Aurore Perrot's co-authors include Hervé Avet‐Loiseau, Jill Corre, Xavier Leleu, Philippe Moreau, Cyrille Hulin, Cyrille Touzeau, Margaret Macro, Salomon Manier, Murielle Roussel and Thierry Façon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Aurore Perrot

112 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aurore Perrot France	20	847	626	553	244	147	130	1.2k
Miguel‐Teodoro Hernández Spain	14	796 0.9×	597 1.0×	544 1.0×	210 0.9×	165 1.1×	44	1.2k
Sharmilan Thanendrarajan United States	19	657 0.8×	469 0.7×	526 1.0×	124 0.5×	97 0.7×	110	1.0k
Kamel Laribi France	17	604 0.7×	336 0.5×	606 1.1×	321 1.3×	329 2.2×	62	1.2k
Alfonso García de Coca Spain	16	657 0.8×	552 0.9×	309 0.6×	346 1.4×	139 0.9×	47	984
Claudia Cellini Italy	20	1.2k 1.4×	862 1.4×	813 1.5×	271 1.1×	286 1.9×	30	1.6k
Athanasios Zomas Greece	18	852 1.0×	502 0.8×	443 0.8×	366 1.5×	303 2.1×	55	1.3k
Josefina Galende Spain	13	635 0.7×	469 0.7×	329 0.6×	292 1.2×	144 1.0×	34	893
Cyrille Hulin France	21	2.1k 2.5×	1.5k 2.3×	1.2k 2.2×	197 0.8×	68 0.5×	106	2.3k
Víctor H. Jiménez‐Zepeda Canada	20	728 0.9×	914 1.5×	588 1.1×	272 1.1×	72 0.5×	102	1.3k
Roberto Sorasio Italy	14	542 0.6×	286 0.5×	291 0.5×	83 0.3×	210 1.4×	33	853

Countries citing papers authored by Aurore Perrot

Since Specialization

Citations

This map shows the geographic impact of Aurore Perrot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurore Perrot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurore Perrot more than expected).

Fields of papers citing papers by Aurore Perrot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurore Perrot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurore Perrot. The network helps show where Aurore Perrot may publish in the future.

Co-authorship network of co-authors of Aurore Perrot

This figure shows the co-authorship network connecting the top 25 collaborators of Aurore Perrot. A scholar is included among the top collaborators of Aurore Perrot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurore Perrot. Aurore Perrot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perrot, Aurore, et al.. (2025). Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France. Clinical Lymphoma Myeloma & Leukemia. 25(8). 606–614.e1. 1 indexed citations

Talbot, Alexis, Cyrille Hulin, Aurore Perrot, et al.. (2025). Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 25(12). 863–872. 1 indexed citations

Perrot, Aurore. (2024). Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma. La Presse Médicale. 54(1). 104262–104262. 1 indexed citations

Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Touzeau, Cyrille, Aurore Perrot, Cyrille Hulin, et al.. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 143(20). 2029–2036. 28 indexed citations

Kapoor, Prashant, Nitya Nathwani, Tomáš Jelı́nek, et al.. (2024). An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. European Journal Of Haematology. 113(5). 593–605. 1 indexed citations

Costa, Luciano J., Nizar J. Bahlis, Saad Z. Usmani, et al.. (2024). Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 24. S235–S235. 1 indexed citations

Raje, Noopur, Adam D. Cohen, Shaji Kumar, et al.. (2024). MM-493 Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT): Phase 3 KarMMa-9 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S562–S563. 1 indexed citations

10.

Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209. 3 indexed citations

11.

Bahlis, Nizar J., Luciano J. Costa, Thierry Façon, et al.. (2023). Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH). PubMed. 5(2-3). 112–121. 1 indexed citations

12.

Leleu, Xavier, Nathalie Texier, Cyrille Touzeau, et al.. (2023). Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study. SHILAP Revista de lepidopterología. 5(1). 55–60. 2 indexed citations

13.

Samur, Mehmet, Marco Roncador, Anıl Aktaş Samur, et al.. (2023). High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 141(14). 1724–1736. 22 indexed citations

14.

Mellqvist, Ulf‐Henrik, T. Steinmetz, Aurore Perrot, et al.. (2023). Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel. Clinical Lymphoma Myeloma & Leukemia. 23(5). e240–e251.e12. 3 indexed citations

15.

Perrot, Aurore, Paul G. Richardson, Joseph Mıkhael, et al.. (2023). P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES. HemaSphere. 7(S3). e3398301–e3398301. 1 indexed citations

16.

Tomowiak, Cécile, Stéphanie Poulain, Charles Herbaux, et al.. (2021). Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood Advances. 5(9). 2438–2446. 21 indexed citations

17.

Harrison, Simon J., Aurore Perrot, Adrían Alegre, et al.. (2021). Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics. British Journal of Haematology. 194(1). 120–131. 32 indexed citations

18.

Rieu, Jean‐Baptiste, Aurore Perrot, François Vergez, Laëtitia Largeaud, & Jill Corre. (2020). When dystrophic plasma cells do not recognize themselves in the mirror. SHILAP Revista de lepidopterología. 1(2). 408–408. 1 indexed citations

19.

Bailly, Clément, Thomas Carlier, Bastien Jamet, et al.. (2018). Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research. 24(21). 5219–5224. 20 indexed citations

20.

Deau, Bénédicte, Sandy Amorim, Aurore Perrot, et al.. (2018). Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study. British Journal of Haematology. 181(3). 341–349. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact